Skip to main content

15.11.2016 | SCLC | Online-Artikel

Rare driver mutations: encouraging results in small patient populations


As well as ALK fusion mutations and EGFR mutations, studies of the genetic profiles of patients with NSCLC have identified other mutations that might be used for additional targeted therapies. Among these, ROS1 and RET rearrangements both occur in 1 % to 2 % of patients with NSCLC.

Weiterführende Themen